ISSN:2154-8331    

DOI:10.1080/21548331.1992.11705594

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

摘要:

At present, the nucleoside analogues are the cornerstone of therapy for HIV Infection. Of the three that have been approved for clinical use, AZT is the only one that has clearly proved to prolong survival, ddI is indicated for patients who develop toxicity or resistance to AZT. Current data do not support ddC monotherapy as first-line treatment.

ISSN:2154-8331    

DOI:10.1080/21548331.1992.11705595

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

摘要:

Combination antiretroviral therapy is an important development in the management of HIV infection. AZT with ddC is the first such combination to be approved for clinical use. Several issues remain, however, including the precise clinical benefit and toxicity of combination therapy, its effect on drug resistance, and the development of ever more effective therapeutic strategies.

ISSN:2154-8331    

DOI:10.1080/21548331.1992.11705596

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor

摘要:

The three approved nucleoside analogues are fairly well tolerated, and only a few patients have to discontinue therapy permanently. However, because clinical experience is limited, especially with ddI and ddC, delayed toxicities are likely to emerge over time. In addition, physicians should be vigilant for overlapping toxicities from combination therapy with these and other medications.

ISSN:2154-8331    

DOI:10.1080/21548331.1992.11705597

出版商:Taylor&Francis    

年代:1992

数据来源: Taylor